Immune Therapeutics Stock Return On Asset
| IMUNDelisted Stock | USD 0.06 0 4.76% |
Immune Therapeutics fundamentals help investors to digest information that contributes to Immune Therapeutics' financial success or failures. It also enables traders to predict the movement of Immune Pink Sheet. The fundamental analysis module provides a way to measure Immune Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immune Therapeutics pink sheet.
Immune |
Immune Therapeutics Company Return On Asset Analysis
Immune Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Immune Therapeutics Return On Asset | -0.45 |
Most of Immune Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Immune Therapeutics has a Return On Asset of -0.4526. This is 94.83% lower than that of the Biotechnology sector and 98.08% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Immune Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immune Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Immune Therapeutics could also be used in its relative valuation, which is a method of valuing Immune Therapeutics by comparing valuation metrics of similar companies.Immune Therapeutics is currently under evaluation in return on asset category among related companies.
Immune Fundamentals
| Return On Asset | -0.45 | |||
| Current Valuation | 83.25 M | |||
| Shares Outstanding | 82.76 M | |||
| Shares Owned By Insiders | 29.51 % | |||
| Price To Earning | 333.33 X | |||
| Price To Sales | 161.50 X | |||
| Gross Profit | 65.83 K | |||
| EBITDA | 3.8 M | |||
| Net Income | 3.59 M | |||
| Cash And Equivalents | 271.53 K | |||
| Total Debt | 1.08 M | |||
| Debt To Equity | 1.97 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (231.72 K) | |||
| Earnings Per Share | 0.03 X | |||
| Number Of Employees | 15 | |||
| Beta | 0.52 | |||
| Market Capitalization | 39.1 M | |||
| Total Asset | 3.14 M | |||
| Retained Earnings | (319.86 M) | |||
| Working Capital | (7.47 M) | |||
| Current Asset | 22 K | |||
| Current Liabilities | 7.49 M | |||
| Net Asset | 3.14 M |
About Immune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immune Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immune Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |